tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RAPP Stock Latest News

Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
RatingsRapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
3d ago
RAPP
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
PremiumRatings
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
3d ago
RAPP
PremiumRatings
Buy Rating on RAP-219 Underscored by Differentiated Clinical Profile, Conservative Phase 3 Design, and Favorable Risk–Reward
4d ago
RAPP
PremiumCompany Announcements
Rapport Therapeutics Establishes $110 Million At-The-Market Offering
4d ago
8K
RAPP
PremiumCompany Announcements
Rapport Therapeutics advances RAP-219 into Phase 3 epilepsy
4d ago
8K
RAPP
Rapport Therapeutics plans to initiates its Phase 3 program for RAP-219
PremiumThe FlyRapport Therapeutics plans to initiates its Phase 3 program for RAP-219
4d ago
RAPP
Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright
Premium
The Fly
Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright
1M ago
RAPP
Premium
Ratings
Promising Outlook for Rapport Therapeutics: Buy Rating Backed by RAP-219’s Clinical Success and Strategic Growth Plans
1M ago
RAPP
Rapport Therapeutics announces new data, post hox analysis on RAP-219
PremiumThe Fly
Rapport Therapeutics announces new data, post hox analysis on RAP-219
1M ago
RAPP
PremiumRatings
Buy Rating for Rapport Therapeutics: Promising Efficacy and Market Potential of RAP-219 in Epilepsy and Bipolar Mania
2M ago
RAPP
Rapport Therapeutics initiated with a Buy at BTIG
PremiumThe Fly
Rapport Therapeutics initiated with a Buy at BTIG
2M ago
RAPP
PremiumRatings
Buy Rating for Rapport Therapeutics: Promising RAP-219 Results and Strong Financial Position
2M ago
RAPP
Rapport Therapeutics price target raised to $80 from $77 at Citizens JMP
PremiumThe FlyRapport Therapeutics price target raised to $80 from $77 at Citizens JMP
2M ago
RAPP
Premium
Company Announcements
Rapport Therapeutics Reports Q3 2025 Financial Results
2M ago
RAPP
Premium
Ratings
Promising Phase II Results and Strong Financial Position Drive Buy Rating for Rapport Therapeutics
2M ago
RAPP
Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)
PremiumThe Fly
Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)
2M ago
RAPP
PremiumCompany Announcements
Rapport Therapeutics’ New Study on RAP-219: A Potential Game-Changer for Epilepsy Treatment
3M ago
RAPP
PremiumCompany Announcements
Rapport Therapeutics’ RAP-219 Study: A Potential Game-Changer for Bipolar I Disorder
3M ago
RAPP
3 Best Stocks to Buy Now, 9/16/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 9/16/2025, According to Top Analysts
4M ago
CHRD
NVDA
Rapport Therapeutics initiated with a Buy at Truist
PremiumThe FlyRapport Therapeutics initiated with a Buy at Truist
4M ago
RAPP
Rapport Therapeutics director buys $1.03M in common stock
Premium
The Fly
Rapport Therapeutics director buys $1.03M in common stock
4M ago
RAPP
Rapport Therapeutics assigned Buy rating at Goldman Sachs
Premium
The Fly
Rapport Therapeutics assigned Buy rating at Goldman Sachs
4M ago
RAPP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >